| Sorafenib in advanced hepatocellular carcinoma JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ... New England journal of medicine 359 (4), 378-390, 2008 | 15452 | 2008 |
| EASL clinical practice guidelines: management of hepatocellular carcinoma European Association For The Study Of The Liver Journal of hepatology 69 (1), 182-236, 2018 | 7271 | 2018 |
| Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma RS Finn, S Qin, M Ikeda, PR Galle, M Ducreux, TY Kim, M Kudo, V Breder, ... New England Journal of Medicine 382 (20), 1894-1905, 2020 | 5575 | 2020 |
| EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma European Association For The Study Of The Liver Journal of hepatology 56 (4), 908-943, 2012 | 4817 | 2012 |
| BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update M Reig, A Forner, J Rimola, J Ferrer-Fàbrega, M Burrel, Á Garcia-Criado, ... Journal of hepatology 76 (3), 681-693, 2022 | 2702 | 2022 |
| Simplified criteria for the diagnosis of autoimmune hepatitis EM Hennes, M Zeniya, AJ Czaja, A Parés, GN Dalekos, EL Krawitt, ... Hepatology 48 (1), 169-176, 2008 | 2274 | 2008 |
| Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma J Bridgewater, PR Galle, SA Khan, JM Llovet, JW Park, T Patel, TM Pawlik, ... Journal of hepatology 60 (6), 1268-1289, 2014 | 1652 | 2014 |
| Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo … AX Zhu, YK Kang, CJ Yen, RS Finn, PR Galle, JM Llovet, E Assenat, ... The lancet oncology 20 (2), 282-296, 2019 | 1632 | 2019 |
| Cutting edge: TGF-β induces a regulatory phenotype in CD4+ CD25− T cells through Foxp3 induction and down-regulation of Smad7 MC Fantini, C Becker, G Monteleone, F Pallone, PR Galle, MF Neurath The Journal of Immunology 172 (9), 5149-5153, 2004 | 1623 | 2004 |
| Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis … R Atreya, J Mudter, S Finotto, J Müllberg, T Jostock, S Wirtz, M Schütz, ... Nature medicine 6 (5), 583-588, 2000 | 1596 | 2000 |
| Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo R Kiesslich, J Burg, M Vieth, J Gnaendiger, M Enders, P Delaney, ... Gastroenterology 127 (3), 706-713, 2004 | 1249 | 2004 |
| Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells—a mechanism of immune evasion? S Strand, WJ Hofmann, H Hug, M Müller, G Otto, D Strand, SM Mariani, ... Nature medicine 2 (12), 1361-1366, 1996 | 1238 | 1996 |
| p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs M Müller, S Wilder, D Bannasch, D Israeli, K Lehlbach, M Li-Weber, ... The Journal of experimental medicine 188 (11), 2033-2045, 1998 | 1176 | 1998 |
| Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ... Gastroenterology 150 (5), 1147-1159. e5, 2016 | 1165 | 2016 |
| Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis R Kiesslich, J Fritsch, M Holtmann, HH Koehler, M Stolte, S Kanzler, ... Gastroenterology 124 (4), 880-888, 2003 | 1135 | 2003 |
| CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes I Tiede, G Fritz, S Strand, D Poppe, R Dvorsky, D Strand, HA Lehr, S Wirtz, ... The Journal of clinical investigation 111 (8), 1133-1145, 2003 | 1046 | 2003 |
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma EOF Research, TO Cancer, ... Journal of hepatology 56 (4), 908-943, 2012 | 1045 | 2012 |
| Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma AL Cheng, S Qin, M Ikeda, PR Galle, M Ducreux, TY Kim, HY Lim, M Kudo, ... Journal of hepatology 76 (4), 862-873, 2022 | 1001 | 2022 |
| p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias H Dohner, K Fischer, M Bentz, K Hansen, A Benner, G Cabot, D Diehl, ... | 996 | 1995 |
| Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. M Müller, S Strand, H Hug, EM Heinemann, H Walczak, WJ Hofmann, ... The Journal of clinical investigation 99 (3), 403-413, 1997 | 959 | 1997 |